Irving Ford, MSc Adaptimmune

Irving Ford is currently the VP of Quality at Adaptimmune and has over 29 years of QA/QC experience in pharmaceutical/biotechnology and cell/gene therapies industries.

Prior to joining Adaptimmune, Irving was a significant contributor for activities supporting the regulatory filings and commercial approval of BMS’ CAR T products Abecma and Breyanzi as well as Novartis’ CAR T product Kymriah.

Irving is an active member of PDA and has served on several planning committees for various PDA Conferences. Irving is a co-author of PDA TR-13- EM of Low Bioburden Facilities, PDA Points to Consider for ATMPs, and for the published White Paper – Risk Assessment Approach to Microbiological Controls of Cellular Therapies.